Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 47 articles:
HTML format
Text format



Single Articles


    November 2018
  1. SCHULZ C, Schutte K, Vilchez-Vargas R, Vasapolli R, et al
    Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Dig Dis. 2018 Nov 14:1-9. doi: 10.1159/000494216.
    PubMed     Text format     Abstract available


    September 2018
  2. GOTTLIEB A, Kottmann M, Manka P, Bedreli S, et al
    How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis.
    Dig Dis. 2018 Sep 18:1-8. doi: 10.1159/000492869.
    PubMed     Text format     Abstract available


    July 2018
  3. BUTTERWORTH RF, Canbay A
    Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2018 Jul 17:1-6. doi: 10.1159/000491429.
    PubMed     Text format     Abstract available


  4. LONGO L, de Freitas LBR, Santos D, Grivicich I, et al
    Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.
    Dig Dis. 2018 Jul 13:1-8. doi: 10.1159/000490378.
    PubMed     Text format     Abstract available


  5. FURUTA M, Moriguchi M, Okuda K, Kataoka S, et al
    Impact of Insufficient Response with an Increase in Tumor Number in Predicting Transcatheter Arterial Chemoembolization Refractoriness for Hepatocellular Carcinoma.
    Dig Dis. 2018 Jul 3:1-10. doi: 10.1159/000489488.
    PubMed     Text format     Abstract available


    May 2018
  6. TAJIRI K, Tokimitsu Y, Ito H, Atarashi Y, et al
    Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Dig Dis. 2018 May 31:1-8. doi: 10.1159/000489258.
    PubMed     Text format     Abstract available


    March 2018
  7. ZOU H, Yang X, Li QL, Zhou QX, et al
    A Comparative Study of Albumin-Bilirubin Score with Child-Pugh Score, Model for End-Stage Liver Disease Score and Indocyanine Green R15 in Predicting Posthepatectomy Liver Failure for Hepatocellular Carcinoma Patients.
    Dig Dis. 2018 Mar 1. pii: 000486590. doi: 10.1159/000486590.
    PubMed     Text format     Abstract available


    January 2018
  8. HUANG XW, Liao B, Huang Y, Liang JY, et al
    Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?
    Dig Dis. 2018 Jan 19. pii: 000486196. doi: 10.1159/000486196.
    PubMed     Text format     Abstract available


  9. BUECHTER M, Manka P, Gerken G, Canbay A, et al
    Transjugular Intrahepatic Portosystemic Shunt in Patients with Portal Hypertension: Patency Depends on Coverage and Interventionalist's Experience.
    Dig Dis. 2018 Jan 9. pii: 000486030. doi: 10.1159/000486030.
    PubMed     Text format     Abstract available


  10. BAI L, Jin W, Kong M, Zhang X, et al
    Injury Resistance in the Setting of Liver Fibrosis Is Accompanied by the Inhibition of High-Mobility Group Box-1 Translocation and Release.
    Dig Dis. 2018;36:167-176.
    PubMed     Text format     Abstract available


  11. TAKATORI Y, Kato M, Sunata Y, Hirai Y, et al
    The Role of History of Gastro-Duodenal Ulcer in Patients with Upper Gastrointestinal Bleeding.
    Dig Dis. 2018;36:177-181.
    PubMed     Text format     Abstract available


  12. PAN X, Han Y, Zou T, Zhu G, et al
    Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis.
    Dig Dis. 2018;36:427-436.
    PubMed     Text format     Abstract available


  13. NISHIOKA Y, Shindoh J, Inagaki Y, Gonoi W, et al
    Host MICA Polymorphism as a Potential Predictive Marker in Response to Chemotherapy for Colorectal Liver Metastases.
    Dig Dis. 2018;36:437-445.
    PubMed     Text format     Abstract available


    November 2017
  14. SHI L, Zhang X, Li J, Bai X, et al
    Favorable Effects of Endoscopic Ligation Combined with Drugs on Rebleeding and Mortality in Cirrhotic Patients: A Network Meta-Analysis.
    Dig Dis. 2017 Nov 21. doi: 10.1159/000484082.
    PubMed     Text format     Abstract available


    October 2017
  15. DYWICKI J, Noyan F, Misslitz AC, Hapke M, et al
    Hepatic T Cell Tolerance Induction in An Inflammatory Environment.
    Dig Dis. 2017 Oct 12. doi: 10.1159/000481341.
    PubMed     Text format     Abstract available


    July 2017
  16. XIAO W, Zheng J, Zhou B, Pan L, et al
    Replication Protein A 3 Is Associated with Hepatocellular Carcinoma Tumorigenesis and Poor Patient Survival.
    Dig Dis. 2017 Jul 7. doi: 10.1159/000478977.
    PubMed     Text format     Abstract available


  17. LABENZ C, Prenosil V, Koch S, Huber Y, et al
    Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Dig Dis. 2017 Jul 4. doi: 10.1159/000477578.
    PubMed     Text format     Abstract available


    January 2017
  18. PERUGORRIA MJ, Labiano I, Esparza-Baquer A, Marzioni M, et al
    Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
    Dig Dis. 2017;35:275-281.
    PubMed     Text format     Abstract available


  19. LARUSSO NF, Tabibian JH, O'Hara SP
    Role of the Intestinal Microbiome in Cholestatic Liver Disease.
    Dig Dis. 2017;35:166-168.
    PubMed     Text format     Abstract available


  20. REICH M, Klindt C, Deutschmann K, Spomer L, et al
    Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage.
    Dig Dis. 2017;35:235-240.
    PubMed     Text format     Abstract available


  21. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    PubMed     Text format     Abstract available


  22. STEINACHER D, Claudel T, Trauner M
    Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2017;35:282-287.
    PubMed     Text format     Abstract available


  23. HALILBASIC E, Steinacher D, Trauner M
    Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
    Dig Dis. 2017;35:288-292.
    PubMed     Text format     Abstract available


  24. PALLEN MJ, Quraishi MN
    The Gut Microbiota and the Hepatologist: Will Our Bugs Prove to be the Missing Link?
    Dig Dis. 2017;35:377-383.
    PubMed     Text format     Abstract available


  25. GALLE PR
    Treating Hepatobiliary Cancers: The Oncology Way.
    Dig Dis. 2017;35:384-386.
    PubMed     Text format     Abstract available


  26. POSE E, Cardenas A
    Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Dig Dis. 2017;35:402-410.
    PubMed     Text format     Abstract available


  27. DUFFY AG, Greten TF
    Treating Hepatobiliary Cancer: The Immunologic Approach.
    Dig Dis. 2017;35:390-396.
    PubMed     Text format     Abstract available


  28. NEVENS F
    Novel Approaches to Reducing the Risk of Variceal Hemorrhage.
    Dig Dis. 2017;35:397-401.
    PubMed     Text format     Abstract available


  29. ROWE IA
    Lessons from Epidemiology: The Burden of Liver Disease.
    Dig Dis. 2017;35:304-309.
    PubMed     Text format     Abstract available


  30. TOWNSEND SA, Newsome PN
    The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016.
    Dig Dis. 2017;35:371-376.
    PubMed     Text format     Abstract available


  31. CHUNG BK, Karlsen TH
    Genetic Discoveries Highlight Environmental Factors as Key Drivers of Liver Disease.
    Dig Dis. 2017;35:323-333.
    PubMed     Text format     Abstract available


  32. WONG LL, Hegade VS, Jones DEJ
    What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Dig Dis. 2017;35:359-366.
    PubMed     Text format     Abstract available


  33. THORGEIRSSON SS
    Stemness in Liver Cancer.
    Dig Dis. 2017;35:387-389.
    PubMed     Text format     Abstract available


  34. BAWDEN SJ, Scott RA, Aithal GP
    Current and Future Magnetic Resonance Technologies for Assessing Liver Disease in Clinical and Experimental Medicine.
    Dig Dis. 2017;35:314-322.
    PubMed     Text format     Abstract available


  35. IREDALE JP, Pellicoro A, Fallowfield JA
    Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.
    Dig Dis. 2017;35:310-313.
    PubMed     Text format     Abstract available


  36. HIRAOKA A, Kumada T, Kudo M, Hirooka M, et al
    Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
    Dig Dis. 2017;35:602-610.
    PubMed     Text format     Abstract available


  37. NISHIDA N, Kudo M
    Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma.
    Dig Dis. 2017;35:618-622.
    PubMed     Text format     Abstract available


  38. UESHIMA K, Nishida N, Kudo M
    Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
    Dig Dis. 2017;35:611-617.
    PubMed     Text format     Abstract available


  39. ISHIKAWA T, Imai M, Owaki T, Sato H, et al
    Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study.
    Dig Dis. 2017;35:598-601.
    PubMed     Text format     Abstract available


  40. ARIZUMI T, Minami T, Chishina H, Kono M, et al
    Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Dig Dis. 2017;35:589-597.
    PubMed     Text format     Abstract available


  41. ARIZUMI T, Minami T, Chishina H, Kono M, et al
    Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
    Dig Dis. 2017;35:583-588.
    PubMed     Text format     Abstract available


  42. IWAMOTO T, Imai Y, Igura T, Kogita S, et al
    Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellula
    Dig Dis. 2017;35:574-582.
    PubMed     Text format     Abstract available


  43. IDA H, Hagiwara S, Kono M, Minami T, et al
    Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Dig Dis. 2017;35:565-573.
    PubMed     Text format     Abstract available


  44. UMEHARA Y, Hagiwara S, Nishida N, Sakurai T, et al
    Hepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis C.
    Dig Dis. 2017;35:548-555.
    PubMed     Text format     Abstract available


  45. KOBAYASHI N, Kumada T, Toyoda H, Tada T, et al
    Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Dig Dis. 2017;35:521-530.
    PubMed     Text format     Abstract available


  46. KITAHATA S, Hiraoka A, Kudo M, Murakami T, et al
    Abdominal Ultrasound Findings of Tumor-Forming Hepatic Malignant Lymphoma.
    Dig Dis. 2017;35:498-505.
    PubMed     Text format     Abstract available


  47. YADA N, Tamaki N, Koizumi Y, Hirooka M, et al
    Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease.
    Dig Dis. 2017;35:515-520.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: